{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0008","statisticalMethod":"Fisher Exact","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"Participant incidence of achieving an increase in platelet count ≥20 x 10\\^9/L above baseline for two consecutive weeks during the 12 week treatment period.","groups":[{"description":"Romiplostim by subcutaneous injection once weekly at a starting dose of 1 µg/kg, adjusted based on weekly platelet counts to a maximum weekly dose of 10 µg/kg","id":"OG000","title":"Romiplostim"},{"description":"Placebo by subcutaneous injection once weekly","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"Efficacy Analysis Set, composed of all randomized participants","reportingStatus":"POSTED","timeFrame":"12-week treatment period","title":"Increase in Platelet Count ≥ 20 x 10^9/L Above Baseline for Two Consecutive Weeks","type":"SECONDARY","unitOfMeasure":"Participants"}